R Marshall Austin
Overview
Explore the profile of R Marshall Austin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang W, Austin R, Zhang H, He Y, Xu L, Wu X, et al.
Am J Clin Pathol
. 2022 Jul;
158(4):472-479.
PMID: 35849091
Objectives: Extended testing for high-risk human papillomavirus genotypes (hrHPVGTs) is increasingly investigated for risk stratification in cervical cancer screening. Methods: Age and hrHPVGT results from 16,993 women with atypical squamous...
2.
Tao X, Austin R, Yu T, Zhong F, Zhou X, Cong Q, et al.
Cancer Cytopathol
. 2021 Dec;
130(4):248-258.
PMID: 34874615
Background: Extended high-risk human papillomavirus (hrHPV) genotype testing (hrHPVGT) has emerged as a new strategy to help optimize the efficiency of hrHPV triage. Methods: Women with an atypical squamous cells...
3.
4.
Nationwide Prevalence and Genotype Distribution of High-Risk Human Papillomavirus Infection in China
Zeng Z, Austin R, Wang L, Guo X, Zeng Q, Zheng B, et al.
Am J Clin Pathol
. 2021 Nov;
157(5):718-723.
PMID: 34724029
Objectives: Extended high-risk human papillomavirus (hrHPV) genotype testing has recently been introduced in routine cervical cancer screening. Changes in national and regional hrHPV genotype prevalence offer an objective baseline indicator...
5.
Jones T, Onisko A, Austin R, Yu J
Am J Clin Pathol
. 2021 Sep;
157(3):413-416.
PMID: 34528660
Objectives: Since the publication of our study demonstrating high negative predictive values (>99% for women in their 40s) of benign-appearing endometrial cells (nEMCs), we have begun to include an educational...
6.
Li A, Li J, Austin R, Wang T, Ashman D, Zhang H, et al.
Cancer Cytopathol
. 2021 Mar;
129(8):622-631.
PMID: 33764649
Background: High-risk human papillomavirus (hrHPV) messenger RNA (mRNA) testing, the Food and Drug Administration-approved testing platform since 2013, has been increasing as a cervical screening alternative to hrHPV DNA testing...
7.
Malinowski D, Broache M, Vaughan L, Andrews J, Gary D, Kaufman H, et al.
Am J Clin Pathol
. 2020 Dec;
155(1):150-154.
PMID: 33270087
No abstract available.
8.
Jones T, Onisko A, Austin R
Acta Cytol
. 2020 Dec;
65(2):158-164.
PMID: 33260179
Introduction: Cervical screening has decreased the incidence of cervical carcinoma around the world primarily by preventing cervical squamous carcinoma, with significantly less measurable protective benefits in prevention of cervical adenocarcinoma....
9.
Austin R, Onisko A, Zhao C
J Am Soc Cytopathol
. 2020 Aug;
9(6):602-606.
PMID: 32839150
No abstract available.
10.
Kaufman H, Alagia D, Chen Z, Onisko A, Austin R
Am J Clin Pathol
. 2020 Jul;
154(4):510-516.
PMID: 32637991
Objectives: Given the recent debate challenging the contribution of cytology in cervical screening, we evaluated results of liquid-based cytology (LBC) and human papillomavirus (HPV) testing in cotesting preceding cervical cancer...